DAEWOONG PHARMA
Develops and manufactures drugs, biologics, and active pharmaceutical ingredients.
069620 | KO
Overview
Corporate Details
- ISIN(s):
- KR7069620003
- LEI:
- Country:
- South Korea
- Address:
- 경기도 화성시 향남읍 제약공단4길 35-14, 화성시
- Sector:
- Manufacturing
Description
Daewoong Pharma is an R&D-centric pharmaceutical company specializing in the development, manufacturing, and commercialization of medical products. The company's portfolio encompasses prescription drugs, with a focus on gastrointestinal and endocrine therapies, alongside biologics, healthcare products, and active pharmaceutical ingredients (APIs). A core tenet of its business model is 'Open Collaboration,' actively seeking partnerships with academic and industry entities to foster innovation. Daewoong Pharma's research efforts are directed towards breakthrough therapies, utilizing advanced drug delivery technologies and expertise in biologics. The company also offers integrated formulation and manufacturing services, supporting partners from initial development to commercial production.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-02-15 00:00 |
[기재정정]소송등의판결ㆍ결정(일정금액이상의청구)
|
Korean | 15.1 KB | ||
| 2023-02-15 00:00 |
투자판단관련주요경영사항
|
Korean | 7.3 KB | ||
| 2023-02-15 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변경
|
Korean | 13.9 KB | ||
| 2023-02-15 00:00 |
영업(잠정)실적(공정공시)
|
Korean | 14.3 KB | ||
| 2023-02-15 00:00 |
불성실공시법인지정예고
|
Korean | 7.0 KB | ||
| 2023-02-13 00:00 |
조회공시요구(풍문또는보도)에대한답변(미확정)
|
Korean | 4.1 KB | ||
| 2023-02-10 00:00 |
조회공시요구(풍문또는보도)
|
Korean | 3.6 KB | ||
| 2023-01-31 00:00 |
투자판단관련주요경영사항(섬유증질환 치료제의 중국내 임상개발 및 상업화 권리에 관한 기술수출 계약)
|
Korean | 10.5 KB | ||
| 2023-01-05 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 98.7 KB | ||
| 2022-12-09 00:00 |
투자판단관련주요경영사항
|
Korean | 8.2 KB | ||
| 2022-12-01 00:00 |
투자판단관련주요경영사항(제2형 당뇨병 치료제 'DWP16001(SGLT2 저해제)' 식품의약품안전처 국내 품목허가 승인)
|
Korean | 10.0 KB | ||
| 2022-11-16 00:00 |
기업설명회(IR)개최(안내공시)
|
Korean | 6.6 KB | ||
| 2022-11-14 00:00 |
분기보고서 (2022.09)
|
Korean | 1.8 MB | ||
| 2022-10-31 00:00 |
영업(잠정)실적(공정공시)
|
Korean | 14.5 KB | ||
| 2022-10-07 00:00 |
최대주주등소유주식변동신고서
|
Korean | 30.8 KB |
Automate Your Workflow. Get a real-time feed of all DAEWOONG PHARMA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DAEWOONG PHARMA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DAEWOONG PHARMA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
